Resource center

Join Professor Bernardi from Vienna for an informative webinar on the management of acute dialysis in cardiac surgery patients. This presentation will provide a comprehensive overview of current clinical practices, identify existing gaps, and discuss potential approaches to improve the quality of renal replacement therapy. 

While current approaches to acute dialysis in cardiac surgery patients are well-established, there remain opportunities to refine strategies, particularly in determining the optimal timing for initiating and discontinuing renal replacement therapy.

Professor Bernardi presents recent research on Proenkephalin A 119-159 (penKid), a biomarker showing promise in identifying optimal timing for discontinuing continuous renal replacement therapy in cardiac surgery patients with AKI. This landmark study, presented at international conferences and recently published, explores penKid's potential to refine current acute dialysis management strategies.

Discover new diagnostic insights presented by Dr. Christian Nusshag at the 29th AKI & CRRT in San Diego. During his presentation on the "Role of Proenkephalin in Assessing Recovery from AKI and AKI-D," Dr. Nusshag dives into real-world data that sheds new light on the critical role of Proenkephalin A 119-159 (penKid) in predicting Acute Kidney Injury (AKI) recovery. Dr. Nusshag emphasizes the limitations of current kidney function biomarkers, highlighting the need for more accurate predictors, especially during Renal Replacement Therapy (RRT). 

With faster kinetics, penKid emerges as a promising biomarker, unaffected by RRT modalities, offering a potential clearer window into residual kidney function and recovery trajectories. Among the unique characteristics of penKid is its potential to improve risk stratification and help identify patients at risk of liberation failure or those experiencing unnecessary prolongation of RRT. Watch the full presentation now and stay ahead in the field of kidney health assessment.

Join Dr. Christian Nußhag for a webinar where he presents real-world data on the kidney function biomarker proenkephalin A 119-159 (penKid) for diagnosing Delayed Graft Function (DGF) in patients after kidney transplantation. According to these first findings, penKid seems to outperform traditional markers in identifying delayed graft function within just 24 hours post-transplantation.

These data, presented at Kidney Week 2023 of the American Society of Nephrology (ASN), offer hope for the development of new strategies to improve early post-transplant care. DGF often leads to prolonged hospital stays, compromised long-term graft function and reduced quality of life for patients. There is a need for more accurate and timely methods to identify DGF and its extent, which the biomarker proenkephalin A 119-159 (penKid) aims to address.

Even though AKI affects 1 in 3 patients in the intensive care units, there is a significant unmet need generated by late and unspecific standard diagnostic tools. With the goal of obtaining a more prompt and precise detection of worsening and improvement of kidney function, the Clinic for Operative Intensive Care and Intermediate Care at University Hospital RWTH Aachen has implemented an innovative biomarker in the clinical routine.

Prof. Dr. Gernot Marx discusses the change in practice needed to implement the kidney function biomarker Proenkephalin A 119-159 (penKid) in the daily routine. He will also approach the clinical applications where penKid shows potential to improve patient management.

The standard of care to determine kidney function has significant limitations, including late detection of changes in kidney function and the influence of non-renal factors on its results. The biomarker Proenkephalin provides a solution to assess changes in kidney function earlier compared to creatinine. 

Prof. Peter Pickkers (Radboud University, Nijmegen) presents the research background alongside a new GFR formula that translates penKid concentrations into an estimated GFR for the routine clinical use initially in adults.

Acute Heart Failure (AHF) is a leading cause of hospitalization in the elderly population and it is commonly associated with poor outcomes. Early identification of high-risk patients and more reliable parameters to monitor disease progression and its outcomes may allow more effective management and a better outcome for AHF patients. 

In this webinar, Prof. Parissis presents different clinical phenotypes of AHF and the role of the kidney function biomarker penKid and the biomarker bio-ADM for endothelial function in selecting and guiding optimal therapeutic interventions. He discusses two clinical cases of AHF using these biomarkers for early risk stratification and evaluation of treatment activities.

Kindly note: SphingoTec currently offers only microtiter plate assays. The Nexus IB10 product line is no longer available.

Near patient diagnostics can greatly improve the time to intervention and the outcomes for the severely sick patients presented at the ED. Learn about the possibilities of near the patient testing of well-known and novel biomarkers at the point-of-care.

Kindly note: SphingoTec currently offers only microtiter plate assays. The Nexus IB10 product line is no longer available.

Acute Kidney Injury is a serious complication of multiple severe conditions such as sepsis, yet is difficult to recognize with the current standard of care diagnostics in the patients presented at the ED. The novel functional kidney biomarker Proenkephalin A can bridge the gap in timely diagnostics of AKI in the ED.

Kindly note: SphingoTec currently offers only microtiter plate assays. The Nexus IB10 product line is no longer available.

Recognizing the high risk sepsis patients at the Emergency Department (ED) poses a certain challenge, yet a timely therapeutic intervention is crucial for the patients’ survival. Find out how a novel biomarker of endothelial function bioactive adrenomedullin can support diagnostics and clinical decisions in the ED.

Kindly note: SphingoTec currently offers only microtiter plate assays. The Nexus IB10 product line is no longer available.